Skip to main content
. 2015 Oct 15;5(11):3339–3349.

Figure 1.

Figure 1

Phenformin inhibits proliferation and turns off ERK signaling in tumor cells carrying KRASG12C. A. Proliferation of H1792 and H358 cells were assessed with metformin. Data are from three independent experiments and are mean ± SD. N = 3. B. H1792 and H358 cells were assessed with phenformin and the growth was assayed by MTT. Data are from three independent experiments and are mean ± SD. N = 3. C. The proliferation inhibitory effects of phenformin on H1792 and H358 cells were abolished by KRASG12C siRNA. Data are from three independent experiments and are mean ± SD. N = 3, **P < 0.01 versus control. D. Proliferation of H1299 and A549 cells were treated with indicated phenformin and was assessed by MTT. Data are from three independent experiments and are mean ± SD. N = 3. E. Biochemical analysis of phospho-ERK and phospho-AKT (Ser473 and Thr308) in H1792 and H358. GAPDH was used as loading control. F. Co-immunoprecipitation (IP) of B-Raf and C-Raf with KRAS from KRASG12C cell lines after treatment with phenformin. Data were from three independent experiments. WCL, whole cell lysate.